

Chemical Constituents from Rhizomes of *Curculigo breviscapa*

Cui-Cui Zhu, Kai-Jin Wang,* Zhi-Yuan Wang, and Ning Li*

Anhui Province Key Laboratory of Research and Development of Chinese Medicine, School of Life Sciences, Anhui University, Hefei 230039, P. R. China. *E-mail: wkjahla@sina.com(KW); ln0110@sina.com(NL)

Received May 29, 2009, Accepted November 22, 2009

Key Words: *Curculigo breviscapa*, Hypoxidaceae, Constituents, Breviscapin A

We have studied several species of the genus *Curculigo*, well known for their use in Chinese folk medicine, on their phytochemical and pharmacological characteristics.¹⁻⁶ *Curculigo breviscapa* S. C. Chen (Hypoxidaceae) is distributed in southwest region of Guangxi Province of China.⁷ However, so far, the chemical constituents of this plant have not been reported. The interesting medicinal properties of this genus encouraged us to undertake the phytochemical investigation on *C. breviscapa*, which led to the isolation and identification of one novel phenolic compound, breviscapin A (**1**), together with five known compounds, crassifogenin B (**2**),² crassifoside A (**3**),² 3-hydroxy-5-methylphenol-1-*O*-[β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside] (**4**),⁸ ocinol glucoside (**5**),⁹ and 3,4-dihydroxybenzoic acid (**6**) from its rhizomes as shown in Figure 1. Their structures were established by spectroscopic analysis, especially using 2D-NMR techniques (¹H-¹H COSY, HMQC, HMBC) and comparisons of their data with literature values. All the compounds in Figure 1 were isolated for the first time from this plant. Herein, the structural elucidation of a novel phenolic compound **1** was provided.

Experimental

General experimental procedures. UV-2401PC spectrometer was used to obtain the UV spectra in methanol (MeOH). IR spectra were recorded on Nexus 870-FT-IR spectrophotometer with potassium bromide (KBr) pellets. Mass spectrometry (MS) was performed on VG Autospec-3000 spectrometer and API-QSTAR-Pulsar-1 spectrometer using a positive ion model. 1D and 2D NMR spectra were measured on Bruker AM-400 spectrometer with TMS as an internal standard. Column chromatography was carried out on Sephadex LH-20 gel (25 - 100 μ m, Pharmacia Fine Chemical Co. Ltd.). Thin layer chromatography

(TLC) was carried out on silica gel G precoated plates (Qingdao Haiyang Chemical Co. Ltd.) and spots were detected by spraying with 5% H₂SO₄ in EtOH followed by heating.

Plant material. The plant material was collected in Napo, Guangxi Province, China, in August 2007 and identified by Prof. Kai-Jin Wang from the School of Life Sciences, Anhui University, where a voucher specimen (No. 20070801) was deposited.

Extraction and isolation. The air-dried and powered rhizomes of *C. breviscapa* (1.3 kg) were extracted with 85% EtOH (3 \times 7 L) under reflux for 3 h. The combined organic layer was concentrated in *vacuo* to afford a residue (52 g). The residue was suspended in H₂O and then passed through a D101 resin column eluting sequentially with water followed by 20%, 40%, 60%, 80% and 95% aqueous MeOH. The fraction (8.5 g) eluted from 20% MeOH was repeatedly purified by Sephadex LH-20 chromatography (EtOH-H₂O, 0:1-1:0) to yield four fractions (A₁-A₄). Fraction A₁ was subjected on Sephadex LH-20 chromatography (MeOH-H₂O, 0:1-1:0, then EtOH-acetone, 1:1) to afford compounds **4** (18 mg) and **5** (13 mg). Compound **6** (17 mg) was obtained from fraction A₂ by column chromatography on Sephadex LH-20 (MeOH). Compounds **1** (5 mg) and **3** (9 mg) were obtained from fraction A₃ by column chromatography on Sephadex LH-20 (EtOH). The fraction A₄ was subjected to chromatography on Sephadex LH-20 (EtOH) repeatedly to yield compound **2** (11 mg).

Breviscapin A (1). Black powder, IR (KBr) ν_{\max} 3415 (OH), 1676 (C=O), 1605 (C=C), 1519, 1437, 1365, 1290, 1263, 1115, 818, 780, 761 cm⁻¹; UV (MeOH) λ_{\max} (log ϵ) 205 (4.60), 283 (3.87) nm. ¹H- and ¹³C-NMR data see Table 1. HR-TOF-MS (positive mode) m/z 337.0679 [M+Na]⁺ (calcd. 337.0688 for C₁₇H₁₄O₆Na).

Crassifogenin B (2). Pale yellow powder, ¹H-NMR (400 MHz, acetone-*d*₆) δ 6.90 (1H, d, J = 2.8 Hz, H-2), 7.09 (1H, d,




Figure 1. Structures of compounds 1-6.

$J = 2.4$ Hz, H-4), 7.07 (1H, s, H-5), 7.11 (1H, s, H-8), 7.33 (1H, d, $J = 2.0$ Hz, H-2'), 6.87 (1H, d, $J = 8.0$ Hz, H-5'), 7.18 (1H, dd, $J = 8.0, 2.0$ Hz, H-6'); ^{13}C -NMR (100 MHz, acetone- d_6) δ 197.5 (s, C=O), 139.0 (s, C-1), 117.6 (d, C-2), 154.0 (s, C-3), 112.1 (d, C-4), 110.5 (d, C-5), 146.7 (s, C-6), 148.9 (s, C-7), 109.8 (d, C-8), 123.2 (s, C-9), 133.5 (s, C-10), 132.5 (s, C-1'), 118.5 (d, C-2'), 146.3 (s, C-3'), 152.3 (s, C-4'), 116.7 (d, C-5'), 125.9 (d, C-6'); FAB-MS (+) m/z 313 $[\text{M}+\text{H}]^+$.

Crassifoside A (3). White amorphous powder, ^1H -NMR (400 MHz, acetone- d_6) δ 7.07 (1H, d, $J = 2.4$ Hz, H-2), 7.40 (1H, d, $J = 2.4$ Hz, H-4), 7.21 (1H, s, H-5), 7.17 (1H, s, H-8), 7.34 (1H, d, $J = 2.0$ Hz, H-2'), 6.88 (1H, d, $J = 8.4$ Hz, H-5'), 7.22 (1H, dd, $J = 8.4, 2.0$ Hz, H-6'), 5.07 (1H, d, $J = 7.2$ Hz, H-1''), 3.43-3.57 (4H, m, glc.H), 3.69 (1H, dd, $J = 11.6, 5.6$ Hz, Ha-6'), 3.90 (1H, dd, $J = 11.6, 1.6$ Hz, Hb-6'); ^{13}C -NMR (100 MHz, acetone- d_6) δ 197.5 (s, C=O), 138.6 (s, C-1), 118.9 (d, C-2), 154.6 (s, C-3), 114.7 (d, C-4), 111.6 (d, C-5), 147.6 (s, C-6), 149.2 (s, C-7), 109.9 (d, C-8), 124.8 (s, C-9), 133.1 (s, C-10), 132.4 (s, C-1'), 118.9 (d, C-2'), 146.8 (s, C-3'), 152.7 (s, C-4'), 117.1 (d, C-5'), 126.1 (d, C-6'), 103.4 (d, C-1''), 72.6 (d, C-2''), 79.1 (d, C-3''), 75.9 (d, C-4''), 78.8 (d, C-5''), 63.9 (t, C-6''); FAB-MS (-) m/z 473 $[\text{M}-\text{H}]^-$.

3-Hydroxy-5-methylphenol-1- O - β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside (4). White amorphous powder, ^1H -NMR (400 MHz, CD_3OD) δ 2.26 (3H, s, CH_3), 6.49 (1H, s, H-2), 6.35 (1H, s, H-4), 6.45 (1H, s, H-6), 4.89 (1H, d, $J = 7.2$ Hz, H-1'), 4.46 (1H, d, $J = 7.6$ Hz, H-1''); ^{13}C -NMR (100 MHz, CD_3OD) δ 21.7 (q, CH_3), 160.0 (s, C-1), 102.0 (d, C-2), 159.1 (s, C-3), 111.3 (d, C-4), 141.3 (s, C-5), 110.0 (d, C-6), 102.0 (d, C-1'), 74.8 (d, C-2'), 77.8 (d, C-3'), 71.3 (d, C-4'), 77.3 (d, C-5'), 69.6 (t, C-6'), 104.5 (d, C-1''), 75.2 (d, C-2''), 77.3 (d, C-3''), 71.5 (d, C-4''), 77.8 (d, C-5''), 62.6 (t, C-6''); FAB-MS (-) m/z 447 $[\text{M}-\text{H}]^-$.

Orcinol glucoside (5). White amorphous powder, ^1H -NMR (400 MHz, CD_3OD) δ 2.12 (3H, s, CH_3), 6.33 (1H, s, H-2), 6.29 (1H, s, H-4), 6.21 (1H, s, H-6), 4.76 (1H, d, $J = 6.8$ Hz, H-1'), 3.33-3.46 (4H, m, glc.H), 3.63 (1H, dd, $J = 11.6, 2.4$ Hz, Ha-6'), 3.80 (1H, d, $J = 12.0$ Hz, Hb-6'); ^{13}C -NMR (100 MHz, CD_3OD) δ 21.7 (q, CH_3), 160.0 (s, C-1), 102.2 (d, C-2), 159.1 (s, C-3), 109.8 (d, C-4), 141.2 (s, C-5), 111.2 (d, C-6), 102.1 (d, C-1'), 74.8 (d, C-2'), 77.9 (d, C-3'), 71.3 (d, C-4'), 77.9 (d, C-5'), 62.4 (t, C-6'); FAB-MS (-) m/z 285 $[\text{M}-\text{H}]^-$.

3,4-Dihydroxy-benzoic acid (6). Colorless needle, ^1H -NMR (400 MHz, CD_3OCD_3) δ 7.54 (1H, d, $J = 2.0$ Hz, H-2), 6.90 (1H, d, $J = 8.4$ Hz, H-5), 7.48 (1H, dd, $J = 8.4, 2.0$ Hz, H-6); ^{13}C -NMR (100 MHz, CD_3OCD_3) δ 169.0 (s, C=O), 124.1 (s, C-1), 118.4 (d, C-2), 146.4 (s, C-3), 151.6 (s, C-4), 116.6 (d, C-5), 124.6 (d, C-6); EI-MS m/z 154 $[\text{M}]^+$.

Results and Discussion

Breviscapin A (**1**) was obtained as black powder. Its molecular formula was determined as $\text{C}_{17}\text{H}_{14}\text{O}_6$, with 11 degrees of unsaturation, on the basis of ^{13}C -NMR (DEPT) data and the pseudomolecular ion $[\text{M}+\text{Na}]^+$ at m/z 337.0679 in HR-TOF $^+$ -MS (calc. 337.0688). The IR spectrum indicated absorptions of OH groups at 3415, a carbonyl group at 1676 and a conjugated olefinic bond at 1605 cm^{-1} . The carbonyl and olefinic IR bands were

Table 1. ^1H -NMR and ^{13}C -NMR Data of **1** (400 MHz, in CD_3OCD_3 , δ ppm, J in Hz)

position	δ (C)	δ (H)	HMBC (H \rightarrow C)
2	88.3 (s)		
3	196.2 (s)		
4	128.1 (d)	6.14 (dt, $J = 10.4, 2.4$)	C-2, C-6
5	150.2 (d)	7.13 (dt, $J = 10.4, 2.8$)	C-3, C-4, C-6
6	62.8 (t)	4.34 (t, $J = 2.4$)	C-2, C-3, C-4, C-5
1'	133.5 (s)		
2'	117.3 (d)	6.72 (d, $J = 2.0$)	C-2, C-4', C-6'
3'	146.2 (s)		
4'	146.6 (s)		
5'	116.2 (d)	6.76 (d, $J = 8.0$)	C-1', C-3'
6'	121.3 (d)	6.60 (dd, $J = 8.0, 2.0$)	C-1, C-2', C-4'
1''	133.5 (s)		
2''	117.3 (d)	6.72 (d, $J = 2.0$)	C-2, C-4', C-6'
3''	146.2 (s)		
4''	146.6 (s)		
5''	116.2 (d)	6.76 (d, $J = 8.0$)	C-1', C-3'
6''	121.3 (d)	6.60 (dd, $J = 8.0, 2.0$)	C-1, C-2', C-4'




Figure 2. Key HMBC correlations of **1**.

confirmed by the ^{13}C -NMR signals at δ_{C} 196.2, 128.1 and 150.2 ppm (Table 1). The ^1H -NMR spectrum showed the presence of two symmetrical 3,4-disubstituted aromatic rings. 1D-NMR and 2D-NMR (^1H - ^1H COSY, HMQC, HMBC) experiments suggested the presence of a six-membered ring containing oxygen and α,β -unsaturated ketone. Thus, the structure of **1** was elucidated as 2,2-bis(3,4-dihydroxyphenyl)-2H-pyran-3(6H)-one based on further analysis of 2D-NMR experiments.

The ^1H - ^1H COSY correlations of H-4/H-5, and H-5/H-6 showed the connectivity of C(4)-C(5)-C(6). The linkage of C-2 and C-6 to an O-atom was established by the HMBC correlations of H-6/C-2 as shown in Figure 2 and the low-field chemical shifts of C-2 and C-6 at δ_{C} 88.3 and 62.8 ppm, respectively (Table 1). The HMBC correlations of H-5/C-3 and H-4/C-2 indicated the presence of C(4)-C(3)-C(2). Thus, a six-membered ring containing oxygen and α,β -unsaturated ketone was established. The HMBC experiments also showed the long-range couplings of H-2'/C-2 and H-6'/C-2, which suggested that two symmetrical 3,4-disubstituted aromatic rings were connected with C-2, respectively (Figure 2). Acetylation of **1** with Ac_2O in pyridine led to the preparation of tetraacetyl analogue, which indicated that four free OH groups are present in **1**. This was confirmed by its FAB-MS spectrum showing a peak at m/z 483 corresponding to the analogue's protonated ion peak.

Five known compounds, crassifogenin B (**2**),² crassifoside A

(3),² 3-hydroxy-5-methylphenol-1-*O*-[β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside] (4),⁸ ocinol glucoside (5),⁹ and 3,4-dihydroxy-benzioc acid (6), were also isolated from the Rhizomes of *C. breviscapa*. Their structures were elucidated by spectral data and their comparison with literature values. All of these compounds were isolated for the first time from this plant.

Acknowledgments. This work was supported by the National Natural Science Foundation of China (30670217), International Foundation for Science (F/4340-1), the Science and Technology Foundation of Distinguished Young Scholars of Anhui Province (08040106812) and the Foundation of personnel developing of Anhui Province. (2008Z020). The authors are grateful to the staff of the Modern Experiment Technology Center, Anhui University for the spectral data.

References

1. Li, N.; Jia, A. Q.; Liu, Y. Q.; Zhou, J. *Acta Bot. Yunnan.* **2003**, 25, 241.
2. Li, N.; Chen, J. J.; Zhou, J. *Helv. Chim. Acta* **2004**, 87, 845.
3. Li, N.; Chen, J. J.; Zhao, Y. X.; Zhou, J. *J. Asian Nat. Prod. Res.* **2005**, 7, 189.
4. Li, N.; Wang, K. J.; Chen, J. J.; Zhou, J. *Tetrahedron Lett.* **2005**, 46, 6445.
5. Li, N.; Chen, J. J.; Zhou, J. *Z. Naturforsch. B* **2006**, 61b, 611.
6. Wang, K. J.; Li, N. *Arch. Pharm. Res.* **2008**, 31, 1313.
7. Delectis Florae Reipublicae Popularis Sinicae Agendae Academiae Sinicae Edita. *Flora Reipublicae Sinicae*; Science Press: Beijing, 1985; Vol.16, p 33.
8. Roberto, R. G.; Lin, L. Z.; Geoffrey, A.; Coraell, S. *Phytochemistry* **1995**, 39, 405.
9. Xu, J. P.; Dong, Q. Y. *Chinese Traditional and Herbal Drugs* **1986**, 17, 8.